Therapeutic success via targeted approaches and strategic partnerships with clinical laboratories.
The future of personalized medicine and the biopharmaceutical industry may lie in the close interaction between drug developers and clinical laboratories. The output of the Human Genome Project and other basic research into various diseases is generating data on individual variation in the treatment responses of patients; the biopharmaceutical industry and clinical laboratories will be expected to use this information to identify those patients who are best able to respond to a particular targeted therapy. Strategic partnerships between drug companies and clinical laboratories will be the centerpiece of this new era of medical treatment, providing higher-resolution diagnostics as well as more efficacious and safer treatment options.
Miller
Glenn A
GA
Genzyme Analytical Services, 3400 Computer Drive, Westborough, MA 01581, USA. Glenn.Miller@genzyme.com
D035843:Biomedical Research / Q000379:methods* / Q000639:trends; D002984:Clinical Laboratory Information Systems / Q000706:statistics & numerical data; D003299:Cooperative Behavior; D015195:Drug Design; D004345:Drug Industry / Q000379:methods* / Q000639:trends; D004358:Drug Therapy / Q000379:methods* / Q000639:trends; D006801:Humans